Clinical trials: Advanced Solid Tumors (Phase 1)
Solid Tumor
A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors
The study will be conducted in about 51 participants in total. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic profile and preliminary antitumor efficacy of Hemay181 in patients with advanced…
- Trial name
- NCT05749432
- Testing
- Hemay181
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
- Trial name
- NCT06105021
- Testing
- AFNT-211
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Affini-T Therapeutics, Inc.
Solid Tumor
A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors
The goal of this study is to evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of YZJ-5053 Tablets in Participants with Advanced Solid Tumors
- Trial name
- NCT06209385
- Testing
- YZJ-5053 tablets
- Where
- 4 sites in China
- Volunteers
- 14 people
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Solid Tumors
Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors
AC480IV will be administered as a monotherapy and then in combination with docetaxel in patients with locally advanced or metastatic solid tumors for whom there are no standard or curative therapies available.
- Trial name
- NCT01245543
- Testing
- AC480IV, Docetaxel
- Where
- 2 sites in United States
- Sponsor
- Daiichi Sankyo
Solid Tumor
A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
This is a phase 1/2 multicenter, first-in-human study of IBI129. It includes a phase 1 dose escalation and expansion section to identify MTD/RP2D of IBI129, plan to enroll 22~180 subjects, and a phase 2 to explore efficacy…
- Trial name
- NCT05991349
- Testing
- IBI129
- Where
- 7 sites in Australia, China
- Volunteers
- 36 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced and/or Metastatic Solid Organ Cancer
A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer
Aim of the study is to evaluate the safety and find the maximal tolerated dose of VB-111 in Patients with Advanced Metastatic Cancer
- Trial name
- NCT00559117
- Testing
- VB-111
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
Major Advanced Solid Tumors Other Than Colorectal
Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks
Phase I Study of PM01183 in Non-Colorectal Cancer Patients to determine the recommended dose (RD) of PM01183.
- Trial name
- NCT01405391
- Testing
- PM01183
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- PharmaMar
Advanced Solid Tumor, Non-Small Cell Lung Cancer
GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results
Evaluate the safety and tolerability of GH21 in patients with advanced solid tumors. Estimate the maximum tolerated dose (MTD) in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT05183243
- Testing
- GH21 Capsule
- Where
- 9 sites in China
- Volunteers
- 68 people
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.
Advanced Solid Tumors
A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors
The purpose of this study, the first clinical trial of JI-101, is to determine the maximum tolerated dose of JI-101 when given orally to patients with solid tumors.
- Trial name
- NCT00842335
- Testing
- JI-101
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Jubilant Innovation Ltd.
Solid Tumor Malignancy
A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
The main purpose To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A18 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).
- Trial name
- NCT06985368
- Testing
- SIBP-A18
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Shanghai Institute Of Biological Products
Tumors
Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of volitinib administered to patients with locally advanced or metastatic solid tumors and determine MTD (Maximum Tolerated Dose)…
- Trial name
- HMPL-504 (NCT01985555)
- Testing
- Volitinib(HMPL-504)
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Hutchison Medipharma Limited
Advanced Solid Tumors
A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors
This is a Phase 1, open-label study evaluating the efficacy and safety of HRXG-K-1939 in combination with Adebrelimab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) in patients with advanced solid tumors.
- Trial name
- NCT05942378
- Testing
- HRXG-K-1939, Adebrelimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Advanced Solid Tumor
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours.
- Trial name
- NCT06833008
- Testing
- IPN01195
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 42 people
- Sponsor
- Ipsen
Advanced Cancer
A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
This study is a multicenter, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AGEN1777 as a single agent and when used in combination with a PD-1 inhibitor in participants with…
- Trial name
- NCT05025085
- Testing
- AGEN1777, a PD-1 inhibitor
- Where
- 11 sites in United States
- Volunteers
- 25 people
- Sponsor
- Agenus Inc.
Advanced Solid Tumor
LIONS (PLK4 Inhibitor in Advanced Solid Tumors)
The primary objective of this study is to identify a safe and tolerated dose and schedule of the orally administered PLK4 inhibitor RP-1664.
- Trial name
- NCT06232408
- Testing
- RP-1664
- Where
- 5 sites in United States, Denmark
- Volunteers
- 29 people
- Sponsor
- Repare Therapeutics
Advanced Solid Tumor Cancer, Metastatic Solid Tumor
A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors
ZE94-0605 is an oral, selective cyclin-dependent kinase 2 (CDK2) inhibitor. This multicenter, open-label, first-in-human Phase 1 study will evaluate ZE94-0605 in adults with advanced, unresectable or metastatic solid tumors.
- Trial name
- NCT07524140
- Testing
- ZE94-0605
- Where
- 3 sites in Australia, Uzbekistan
- Volunteers
- 60 people
- Sponsor
- Eilean Therapeutics
Advanced or Metastatic Solid Tumors
A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered intravenously.
- Trial name
- INCLINE-101 (NCT05399654)
- Testing
- TAC-001
- Where
- 12 sites in United States, Australia
- Volunteers
- 72 people
- Sponsor
- Tallac Therapeutics
Cutaneous Melanoma, Non-small Cell Lung Cancer
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug.
- Conditions
- Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms
- Trial name
- NCT05571839
- Testing
- PF-08046049
- Where
- 37 sites in United States, Canada and 4 more
- Volunteers
- 41 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
Advanced Solid Malignancies
A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies
This is an open-label, dose-escalation study of the study drug YH002. The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of YH002 in patients with…
- Trial name
- NCT04353102
- Testing
- YH002
- Where
- 3 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.